QUINTAMED

Development, marketing and sales of pharmaceutical products.

The company is 5 years old. 2 legal entities (Ukraine / Estonia).
The company is at the stage of scaling. Sales: 2nd year ~ 20,000 USD, 3rd year ~ 100,000 USD, 4th year ~ 300,000 USD.
The planned increase of the company's value from 2022 to 2030 is 7-14 times.
The planned amount of dividends is 11-25% per annum.

Markets and trands information - in presentation.

The volume of our current segment (our 12 active products) is 281 422 153 USD and will grow next 4 years (approx. +20% per year).

When we will expand our portfolio with 20 more products the market volume of our segment will be approx. 500 000 000 USD.

For each our product there is a market segment (capacity specified in the presentation).

The pharmaceutical market of Ukraine was 4 046 857 440 USD in 2019, 4 236 832 110 USD in 2020. And by results of the two quarters of 2021 shows growing dynamics (Q1+Q2 is 2 330 010 170 USD).

More information about the products - in the presentation.
The portfolio includes 14 products (12 in active promotion, 2 in development), which are used in the following therapeutic areas: cardiology, neurology, gastroenterology, paediatrics, dermatology, traumatology, gynaecology, urology, andrology, cosmetology, dentistry. Also on the market are 8 products of our partners (full potential of the portfolio - 52 positions).

The main competitors are the TOP-50 companies of the pharmaceutical market of Ukraine (TOP-20 in the dietary supplement segment).

Six of the twelve main products have unique differences and have no direct complete analogues at market.

The cost of products and sales forecasts - in the presentation.

At the moment our sales 350 000 USD per annum with only 2 regions, covering less than 7% of the total market. Our goal is to reach 3 000 000 USD sales in 2023 (1% of our market segment) and 9 000 000 USD in 2030 (3.2% of our market segment).

The first goal will be achievable when we will have representatives in each region (100% coverage of the market). And the second one we will achieve after portfolio expansion (+20 products). And the next step will be the export of products to other countries.

Sales channels - national pharmaceutical distributors, national and local pharmacy chains.
We currently have contracts with all major national pharmaceutical distributors, and our products are in the TOP-20 networks of Ukraine.

Of the total investment (1200000)
1) 800,000 - payment to 2 co-owners (66% of the company wil become the property of investor)
2) 400,000 - costs for scaling and development
- expanding the status of representatives to 48 in five stages
- improving the attractiveness as an employer by improving the working conditions of employees (leasing / buying a car)
- strengthening of advertising activity
- expansion of portfolio products

We will agree in the negotiation process (66% of the company).

Never took part.

According to the results of the expert analysis of the All-Ukrainian Sectoral Analytical Center, we are included in the Register of reliable and investment-attractive enterprises of Ukraine

According to the results of the National Business Rating "Company of the Year" we have "bronze" in the category "Performance and profitability" in Ukraine and "gold" in the Kharkiv region.